Establishing the Role of Tigecycline in an era of Antimicrobial Resistance

Jason J. Schafer; Debra A. Goff


Expert Rev Anti Infect Ther. 2008;6(5):557-567. 

In This Article

Expert Commentary

Tigecycline is the first in a new class of antibacterial agents, the glycylcyclines. Although derived from tetracycline agents, tigecycline is structurally modified to overcome common tetracycline-resistance mechanisms, including ribosomal protection and efflux pumps. It possesses a broad spectrum of antibacterial activity ,including activity against some MDR Gram-positive and -negative pathogens. The safety and efficacy of tigecycline has been demonstrated in clinical trials and it is currently indicated for the management of cSSIs and cIAIs in adult patients. Further experience with tigecycline for serious infections with drug-resistant pathogens is currently warranted.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.